Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTI
Previous Symbol
CUSIPN/A
Phone972-74-710-7259
Debt
Debt-to-Equity RatioN/A
Current Ratio3.31
Quick Ratio3.31
Price-To-Earnings
Trailing P/E Ratio-3.86
Forward P/E Ratio-3.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$50,000.00
Price / Sales2,234.25
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.26 per share
Price / Book3.71
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-26,120,000.00
Net MarginsN/A
Return on Equity-91.60%
Return on Assets-69.89%
Miscellaneous
Employees180
Outstanding Shares115,800,000
Market Cap$120.43 million
OptionableOptionable
Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.01. View Pluristem Therapeutics' Earnings History.
When is Pluristem Therapeutics' next earnings date?
What price target have analysts set for PSTI?
3 brokers have issued 12-month price targets for Pluristem Therapeutics' shares. Their forecasts range from $3.00 to $4.50. On average, they anticipate Pluristem Therapeutics' share price to reach $3.8333 in the next twelve months. This suggests a possible upside of 297.4% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.
What is the consensus analysts' recommendation for Pluristem Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.
What are Wall Street analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (7/12/2018)
- 2. Maxim Group analysts commented, "Pluristem announced a joint project with Indiana University to evaluate PLX- R18 cells in Acute Radiation Syndrome (ARS). The study will be supported with $2.5M in grant funding, and data from the first year of the study will be used to further support a BLA filing." (4/23/2018)
Has Pluristem Therapeutics been receiving favorable news coverage?
News stories about PSTI stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pluristem Therapeutics earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include Replimune Group (REPL), PDL BioPharma (PDLI), Mesoblast (MESO), Translate Bio (TBIO), Nightstar Therapeutics (NITE), CASI Pharmaceuticals (CASI), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Krystal Biotech (KRYS), LogicBio Therapeutics (LOGC), Agenus (AGEN), Gamida Cell (GMDA) and Sutro Biopharma (STRO).
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Mr. Zami Aberman, Chairman & Co-CEO (Age 64)
- Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 47)
- Mr. Erez Egozi, CFO, Treasurer & Sec. (Age 44)
- Mr. Boaz Leshem, VP Operations & Manufacturing (Age 58)
- Efrat Kaduri, Head of Investor & PR
Who are Pluristem Therapeutics' major shareholders?
Pluristem Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (2.55%), Renaissance Technologies LLC (1.15%), B. Riley Financial Inc. (0.21%), Virtu Financial LLC (0.15%) and Jane Street Group LLC (0.08%). View Institutional Ownership Trends for Pluristem Therapeutics.
Which institutional investors are buying Pluristem Therapeutics stock?
How do I buy shares of Pluristem Therapeutics?
Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of PSTI stock can currently be purchased for approximately $0.9647.
How big of a company is Pluristem Therapeutics?
Pluristem Therapeutics has a market capitalization of $120.43 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-26,120,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Pluristem Therapeutics employs 180 workers across the globe.
What is Pluristem Therapeutics' official website?
How can I contact Pluristem Therapeutics?
Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-7259 or via email at [email protected]
MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
